Description
Title of Invention: PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR
PROPHYLAXIS OF CANCER
Technical Field
[0001]
The present invention relates to novel use of an antibody against CAPRIN-1 or a
fragment thereof in a drug such as a therapeutic and/or preventive agent for cancer.
Background Art
[0002]
Cancer is the leading cause of death. This disease is currently treated principally by
surgical therapy in combination with radiation therapy and/or chemotherapy. In spite of
recent development of novel surgical techniques or discovery of novel anticancer agents, the
existing treatment of cancer has an insufficiently improved outcome, except for some cancer
types. With recent advances of molecular biology or cancer immunology, antibodies that
specifically react with cancer, cancer antigens that are recognized by cytotoxic T cells, genes
encoding such cancer antigens, and the like have been identified, raising expectations on
specific cancer therapy targeting the cancer antigens (Non Patent Literature 1).
[0003]
For reducing the side effect of cancer therapy, it is desired that peptides, polypeptides,
or proteins recognized as antigens of the cancer should rarely exist in normal cells and
specifically exist in cancer cells. In 1991, Boon et al. (Ludwig Institute for Cancer Research,
Belgium) isolated a human melanoma antigen MAGE1 recognized by CD8-positive T cells by
a cDNA expression cloning method using autologous cancer cell lines and cancer-reactive T
cells (Non Patent Literature 2). Then, a SEREX (serological identification of antigens by
recombinant expression cloning) method has been reported, which adopts a gene expression

cloning approach to identify tumor antigens recognized by antibodies produced in response to
autologous cancer in vivo in a cancer patient (Non Patent Literature 3 and Patent Literature 1).
According to this method, some cancer antigens that are rarely expressed in normal cells and
are specifically expressed in cancer have been isolated (Non Patent Literatures 4 to 9). In
addition, cell therapy using immunocytes that specifically react with cancer antigens or
cancer-specific immunotherapy using vaccines or the like comprising cancer antigens is under
clinical trial targeting some of the isolated cancer antigens.
[0004]
In recent years, various antibody drugs for cancer treatment targeting antigenic proteins
on cancer cells have emerged in the world. These drugs have received attention because of
their certain efficacy as cancer-specific therapeutic agents. A large majority of antigenic
proteins targeted by the drugs, however, are also expressed in normal cells. As a result of
administering the antibodies, normal cells expressing the antigens as well as cancer cells are
damaged, disadvantageously resulting in side effect. Thus, if cancer antigens specifically
expressed on the surface of cancer cells can be identified and antibodies targeting the antigens
can be used as drugs, these antibody drugs can be expected to achieve treatment with less side
effect.
[0005]
Cytoplasmic- activation- and proliferation-associated protein 1 (CAPRIN-1) has been
known as an intracellular protein that is expressed upon activation or cell division of resting
normal cells and forms cytoplasmic stress granules with intracellular RNAs to participate in
the regulation of transport and translation of mRNAs. This protein has been found to be
specifically expressed on the surface of cancer cells and is therefore under study as a target of
antibody drugs for cancer treatment (Patent Literature 2).
Citation List
Patent Literature
[0006]

Patent Literature 1: U.S. Patent No. 5698396
Patent Literature 2: WO2010/016526
Non Patent Literature
[0007]
Non Patent Literature 1: Tsuyoshi Akiyoshi, "Japanese Journal of Cancer and Chemotherapy",
1997, Vol. 24, p. 511-519 (Japanese Journal of Cancer and Chemotherapy Publishers Inc.,
Japan)
Non Patent Literature 2: Bruggen P. et al., Science, 254: 1643-1647 (1991)
Non Patent Literature 3: Proc. Natl. Acad. Sci. USA, 92: 11810-11813 (1995)
Non Patent Literature 4: Int. J. Cancer, 72: 965-971 (1997)
Non Patent Literature 5: Cancer Res., 58: 1034-1041 (1998)
Non Patent Literature 6: Int. J. Cancer, 29: 652-658 (1998)
Non Patent Literature 7: Int. J. Oncol., 14: 703-708 (1999)
Non Patent Literature 8: Cancer Res., 56: 4766-4772 (1996)
Non Patent Literature 9: Hum. Mol. Gene 6: 33-39, 1997
Summary of Invention
Technical Problem
[0008]
An object of the present invention is to produce an antibody which targets CAPRIN-1
specifically expressed on the surface of cancer cells and has better antitumor activity than
conventional antibodies, and provide use of the antibody as a therapeutic and/or preventive
agent for cancer.
Solution to Problem
[0009]
The present invention has the following aspects:

The present invention provides an antibody or a fragment thereof which has
immunological reactivity with a CAPRIN-1 protein, the antibody comprising a heavy chain
variable region comprising amino acid sequences of SEQ ID NOs: 5, 6, and 7 and a light chain
variable region comprising amino acid sequences of SEQ ID NOs: 9, 10, and 11, and a
pharmaceutical composition for treatment and/or prevention of cancer, comprising the same as
an active ingredient.
[0010]
In an embodiment of the present invention, the cancer is breast cancer, kidney cancer,
pancreatic cancer, large bowel cancer, lung cancer, brain tumor, gastric cancer, uterine cervix
cancer, ovary cancer, prostate cancer, urinary bladder cancer, esophageal cancer, leukemia,
lymphoma, fibrosarcoma, mastocytoma, or melanoma.
[0011]
In another embodiment, the antibody is a human antibody, a humanized antibody, a
chimeric antibody, a single-chain antibody, or a bispecific antibody.
[0012]
The present specification encompasses the contents disclosed in Japanese Patent
Application No. 2011-171303 based on which the priority of the present application is claimed.
Advantageous Effects of Invention
[0013]
The antibody against CAPRIN-1 used in the present invention damages cancer cells.
Thus, the antibody against CAPRIN-1 is useful in the treatment and/or prevention of cancer.
Description of Embodiments
[0014]
The antibody against a CAPRIN-1 polypeptide used in the present invention can be
examined for its antitumor activity, as described later, by examining in vivo the inhibition of
tumor proliferation in a cancer-bearing animal or by examining ex vivo the presence or

absence of immunocyte- or complement-mediated cytotoxic activity exhibited by the antibody
against tumor cells expressing the polypeptide.
[0015]
The antibody against CAPRIN-1 used in the present invention is a monoclonal
antibody, and may be any type of antibody that can exert antitumor activity and includes, for
example, recombinant antibodies, for example, synthetic antibodies, multispecific antibodies,
humanized antibodies, chimeric antibodies, and single-chain antibodies (scFv), human
antibodies, and their antibody fragments, for example, Fab, F(ab')2, and Fv. These antibodies
and fragments thereof can be prepared by methods generally known to those skilled in the art.
In the case of a human test subject, a human antibody or a humanized antibody is desirable for
avoiding or suppressing rejection.
[0016]
In this context, the phrase "specifically binding to the CAPRIN-1 protein" means that
the antibody specifically binds to the CAPRIN-1 protein without substantially binding to other
proteins.
[0017]
The test subject to receive the treatment and/or prevention of cancer according to the
present invention is a mammal such as a human, a pet animal, livestock, or a sport animal,
preferably a human.
[0018]
Hereinafter, antigen preparation, antibody preparation, and a pharmaceutical
composition according to the present invention will be described.
[0019]
Preparation of antigen for antibody preparation>
Proteins or fragments thereof used as sensitizing antigens for obtaining the antibody
against CAPRIN-1 used in the present invention are not limited by animal types serving as
their origins, including humans, dogs, cattle, horses, mice, rats, and chickens. The proteins or
the fragments thereof, however, are preferably selected in view of compatibility with parent

cells for use in cell fusion. In general, mammal-derived proteins are preferred. Particularly,
human-derived proteins are preferred. For example, when CAPRIN-1 is human CAPRIN-1,
human CAPRIN-1 proteins, partial peptides thereof, or cells expressing human CAPRIN-1 can
be used.
[0020]
The nucleotide sequences and amino acid sequences of human CAPRTN-1 and
homologs thereof can be obtained, for example, by making an access to GenBank (NCBI,
USA) and using BLAST or FASTA algorithm (Karlin and Altschul, Proc. Natl. Acad. Sci.
USA, 90: 5873-5877, 1993; and Altschul et al., Nucleic Acids Res. 25: 3389-3402, 1997).
[0021]
In the present invention, with reference to the nucleotide sequence (SEQ ID NO: 1 or
3) or amino acid sequence (SEQ ID NO: 2 or 4) of human CAPRIN-1, the targets are nucleic
acids or proteins consisting of sequences having 70% to 100%, preferably 80% to 100%, more
preferably 90% to 100%, further preferably 95% to 100%, for example, 97% to 100%, 98% to
100%, 99% to 100%, or 99.5% to 100% sequence identity to the nucleotide sequence or amino
acid sequence of the ORF or mature portion of the reference. In this context, the term "%
sequence identity" means a percentage (%) of the number of identical amino acids (or bases)
to the total number of amino acids (or bases) when two sequences are aligned such that the
maximum degree of similarity or identity can be achieved with or without introduced gaps.
[0022]
The fragments of each CAPRTN-1 protein have lengths ranging from the amino acid
length of an epitope (or an antigenic determinant), which is the smallest unit recognized by the
antibody, to less than the full-length of the protein. The epitope refers to a polypeptide
fragment having antigenicity or immunogenicity in mammals, preferably humans. Its
smallest unit consists of approximately 7 to 12 amino acid, for example, 8 to 11 amino acid.
[0023]
Polypeptides comprising the above human CAPRTN-1 proteins and partial peptides
thereof can be synthesized according to chemical synthesis methods, for example, Fmoc

(fluorenylmethyloxycarbonyl) and tBoc (t-butyloxycarbonyl) methods (Seikagaku Jikken
Koza (Biochemical Experimentation Course in English) 1, the Japanese Biochemical Society
ed., Protein Chemistry IV, Chemical Modification and Peptide Synthesis, Tokyo Kagaku
Dojin Co., Ltd. (Japan), 1981). Also, these polypeptides can be synthesized by routine
methods using various commercially available peptide synthesizers. Alternatively,
polynucleotides encoding the polypeptides may be prepared using genetic engineering
approaches known in the art (Sambrook et al., Molecular Cloning, the 2nd edition, Current
Protocols in Molecular Biology (1989), Cold Spring Harbor Laboratory Press; Ausubel et al.,
Short Protocols in Molecular Biology, the 3rd edition, A compendium of Methods from
Current Protocols in Molecular Biology (1995), John Wiley & Sons; etc.) and incorporated
into expression vectors, which are then introduced into host cells so that the host cells produce
the polypeptides. In this way, the polypeptides of interest can be obtained.
[0024]
The polynucleotides encoding the polypeptides can be readily prepared by genetic
engineering approaches known in the art or routine methods using commercially available
nucleic acid synthesizers. For example, a DNA comprising the nucleotide sequence of
human CAPRIN-1 gene can be prepared by PCR using a human chromosomal DNA or cDNA
library as a template and a pair of primers designed so as to be capable of amplifying the
nucleotide sequence described in SEQ ID NO: 1. Reaction conditions for this PCR can be
appropriately determined. Examples of the conditions can include, but not limited to, 30
cycles each involving reaction steps consisting of 94°C for 30 seconds (denaturation), 55°C
for 30 seconds to 1 minute (annealing), and 72°C for 2 minutes (elongation) using
thermotolerance DNA polymerase (e.g., Taq polymerase, Pfu polymerase) and a Mg2+-
containing PCR buffer, followed by reaction at 72°C for 7 minutes. The PCR approach,
conditions, etc. are described in, for example, Ausubel et al., Short Protocols in Molecular
Biology, the 3rd edition, A Compendium of Methods from Current Protocols in Molecular
Biology (1995), John Wiley & Sons (particularly, Chapter 15).
[0029]

Also, appropriate probes or primers can be prepared on the basis of information about
the nucleotide sequences of CAPRIN-1 gene and the amino acid sequences of CAPRIN-1
proteins, and used in the screening of, for example, a human cDNA library, to isolate the
desired DNA. Preferably, such a cDNA library is produced from cells, organs, or tissues
expressing CAPRIN-1 proteins. Examples of such cells or tissues include cells or tissues
derived from cancers or tumors such as breast cancer, kidney cancer, pancreatic cancer, large
bowel cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer,
prostate cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma,
mastocytoma, or melanoma. These operations, including the preparation of probes or
primers, the construction of a cDNA library, the screening of the cDNA library, and the
cloning of the gene of interest, are known to those skilled in the art and can be performed
according to methods described in, for example, Sambrook et al., Molecular Cloning, the 2nd
edition, Current Protocols in Molecular Biology (1989), and Ausubel et al. (ibid.). DNAs
encoding the human CAPRIN-1 proteins and the partial peptides thereof can be obtained from
the DNA thus obtained.
[0026]
The host cells may be any cell capable of expressing the above polypeptides.
Examples of prokaryotic cells include, but not limited to, E. coli. Examples of eukaryotic
cells include, but not limited to: mammalian cells such as monkey kidney cells COS1 and
Chinese hamster ovary cells CHO; a human embryonic kidney cell line HEK293; mouse
embryonic skin cell line NIH3T3; yeast cells such as budding yeast and fission yeast cells;
silkworm cells; and Xenopus egg cells.
[0027]
In the case of using prokaryotic cells as the host cells, the expression vectors used have
an origin that permits replication in the prokaryotic cells, a promoter, a ribosomal binding site,
a multicloning site, a terminator, a drug resistance gene, an auxotrophic complementary gene,
etc. Examples of expression vectors for E. coli can include pUC series, pBluescript II, pET
expression systems, and pGEX expression systems. The DNAs encoding the above

polypeptides can be incorporated into such expression vectors, with which prokaryotic host
cells are then transformed, followed by culture of the obtained transformants so that the
polypeptides encoded by the DNAs are expressed in the prokaryotic host cells. In this
respect, the polypeptides may be expressed as fusion proteins with other proteins.
[0028]
In the case of using eukaryotic cells as the host cells, expression vectors for eukaryotic
cells having a promoter, a splicing region, a poly(A) addition site, etc. are used as the
expression vectors. Examples of such expression vectors can include pKAl, pCDM8,
pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV, pRS, pcDNA3, and pYES2 vectors. In
the same way as above, the DNAs encoding the above polypeptides can be incorporated into
such expression vectors, with which eukaryotic host cells are then transformed, followed by
culture of the obtained transformants so that the polypeptides encoded by the DNAs are
expressed in the eukaryotic host cells. In the case of using expression vectors such as
pIND/V5-His, pFLAG-CMV-2, pEGFP-Nl, or pEGFP-Cl, the polypeptides may be
expressed as various fusion proteins tagged with His tag (e.g., (His)6 - (His)io), FLAG tag,
myc tag, HA tag, GFP, or the like.
[0029]
The expression vectors can be introduced into the host cells using well known methods
such as electroporation, a calcium phosphate method, a liposome method, a DEAE dextran
method, microinjection, viral infection, lipofection, and binding with cell-penetrating peptides.
[0030]
The polypeptide of interest can be isolated and purified from the host cells by a
combination of separation operations known in the art. Examples thereof include, but not
limited to, treatment with a denaturant (e.g., urea) or a detergent, ultrasonication, enzymatic
digestion, salting-out, solvent fractionation and precipitation, dialysis, centrifugation,
ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing electrophoresis, ion-exchange
chromatography, hydrophobic chromatography, affinity chromatography, and reverse-phase
chromatography.

[0031]

Antibodies are usually heteromultimeric glycoproteins comprising at least two heavy
chains and two light chains. The antibodies, except for IgM, are heterotetrameric
glycoproteins of approximately 150 kDa each composed of two identical light (L) chains and
two identical heavy (H) chains. Typically, each light chain is connected to a heavy chain via
a single covalent disulfide bond, though the number of disulfide bonds between heavy chains
varies among different immunoglobulin isotypes. Each of the heavy and light chains also has
an intrachain disulfide bond. Each heavy chain has a variable domain (VH region) at one end,
followed by a series of constant regions. Each light chain has a variable domain (VL region)
at one end and has a single constant region at the other end. The light chain constant region
is aligned with the first heavy chain constant region, while the light chain variable domain is
aligned with the heavy chain variable domain. Particular regions called complementarity
determining regions (CDRs) in the antibody variable domains exhibit specific variability and
impart binding specificity to the antibody. Portions relatively conserved in the variable
regions are called framework regions (FRs). The complete heavy and light chain variable
domains each comprise four FRs connected via three CDRs. These three CDRs are called
CDRH1, CDRH2, and CDRH3 in this order from the N-terminus of the heavy chain.
Likewise, the CDRs are called CDRL1, CDRL2, and CDRL3 in the light chain. CDRH3 is
most important for the binding specificity of the antibody for its antigen. In addition, CDRs
in each chain are kept close to each other by the FR regions and contribute to the formation of
an antigen-binding site in the antibody, together with CDRs in the other chain. The constant
regions do not directly contribute to antibody-antigen binding, but exhibit various effector
functions, for example, involvement in antibody-dependent cellular cytotoxicity (ADCC),
phagocytosis mediated by binding to an Fey receptor, half-life/clearance rate mediated by a
neonatal Fc receptor (FcRn), and complement-dependent cytotoxicity (CDC) mediated by a
Clq component in the complement cascade.
[0032]

Preparation of antibody>
The anti-CAPRIN-1 antibody according to the present invention means an antibody
having immunological reactivity with a full-length CAPRIN-1 protein or a fragment thereof.
[0033]
In this context, the "immunological reactivity" means the property of the antibody
binding to the CAPRIN-1 antigen in vivo. Via such binding, the antibody exerts the function
of damaging (e.g., killing, suppressing, or regressing) tumor. Specifically, the antibody used
in the present invention is not limited by its type as long as the antibody can damage tumors
such as breast cancer, kidney cancer, pancreatic cancer, large bowel cancer, lung cancer, brain
tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder
cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma as
a result of binding to the CAPRIN-1 protein.
[0034]
In the present invention, the antibody is not limited by its type as long as the antibody
is monoclonal antibodies, and examples thereof include synthetic antibodies, multispecific
antibodies (e.g., diabody and triabody), human antibodies, humanized antibodies, chimeric
antibodies, single-chain antibodies, and antibody fragments (e.g., Fab, F(ab')2, and Fv). Also,
the antibody is any class of immunoglobulin molecule, for example, IgG, IgE, IgM, IgA, IgD,
or IgY, or any subclass, for example, IgGl, IgG2, IgG3, IgG4, IgAl, or IgA2.
[0035]
The antibody may be further modified by acetylation, formylation, amidation,
phosphorylation, PEGylation, or the like, in addition to glycosylation.
[0036]
Hereinafter, preparation examples of various monoclonal antibodies will be shown.
For example, breast cancer cell lines SK-BR-3 expressing CAPRIN-1 is administered
to each mouse for immunization. The spleen is extracted from this mouse. After separation
of spleen cells, the cells are fused with mouse myeloma cells. Clones producing antibodies
having antiproliferative effect a cancer cell are selected from among the obtained fusion cells

(hybridomas). The hybridomas producing monoclonal antibodies having antiproliferative
effect of a cancer cell are isolated and cultured. The antibody of interest can be prepared by
purification from the culture supernatant according to a general affinity purification method.
[0037]
The monoclonal antibody-producing hybridomas may be prepared, for example, as
follows: first, animals are immunized with sensitizing antigens according to a method known
in the art. This immunization method generally involves intraperitoneally or subcutaneously
injecting the sensitizing antigens to mammals. Specifically, the sensitizing antigens are
diluted with or suspended in PBS (phosphate-buffered saline), physiological saline, or the like
into an appropriate amount and then mixed, if desired, with an appropriate amount of a
conventional adjuvant, for example, a complete Freund's adjuvant. After emulsification, the
resulting emulsion is administered to each mammal several times every 4 to 21 days.
Alternatively, an appropriate carrier may be used for the immunization with sensitizing
antigens.
[0038]
After confirmation of a rise in the level of the desired antibody in the serum of the
mammal thus immunized, immunocytes are collected from the mammal and subjected to cell
fusion. Preferred examples of the immunocytes particularly include spleen cells.
[0039]
Mammalian myeloma cells are used as partner parent cells to be fused with the
immunocytes. Various cell lines known in the art, for example, P3U1 (P3-X63Ag8Ul), P3
(P3x63Ag8.653) (J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.l (Current Topics in
Microbiology and Immunology (1978) 81, 1-7), NS-1 (Kohler. G. and Milstein, C. Eur. J.
Immunol. (1976) 6, 511-519), MPC-11 (Margulies. D.H. et al., Cell (1976) 8, 405-415), SP2/0
(Shulman, M. et al., Nature (1978) 276, 269-270), FO (deSt. Groth, S.F. et al., J. Immunol.
Methods (1980) 35, 1-21), S194 (Trowbridge, I.S. J. Exp. Med. (1978) 148, 313-323), and
R210 (Galfre, G. et al., Nature (1979) 277,131-133), are preferably used as the myeloma cells.
[0040]

The cell fusion between the immunocytes and the myeloma cells can be performed
basically according to a method known in the art, for example, the method of Kohler and
Milstein (Kohler, G. and Milstein, C. Methods Enzymol. (1981) 73, 3-46).
[0041]
More specifically, the cell fusion is carried out, for example, in the presence of a cell
fusion promoter in a conventional nutrient medium. For example, polyethylene glycol (PEG)
or hemagglutinating virus of Japan (HVJ) is used as the fusion promoter. If desired, an
auxiliary such as dimethyl sulfoxide may be further added in order to enhance fusion
efficiency.
[0042]
The ratio between the immunocytes and the myeloma cells used can be arbitrarily set.
For example, the amount of the immunocytes is preferably set to 1 to 10 times the amount of
the myeloma cells. Examples of the medium that can be used in the cell fusion include
RPMI1640 and MEM media suitable for the growth of the myeloma cell lines as well as
conventional media for use in this type of cell culture. In addition, a serum supplement such
as fetal calf serum (FCS) may be used in combination with these cells.
[0043]
For the cell fusion, the immunocytes and the myeloma cells are well mixed in a
predetermined amount of the medium. A PEG solution (average molecular weight: for
example, approximately 1000 to 6000) preheated to approximately 37°C is usually added to
the mixture at a concentration of 30 to 60% (w/v) and mixed therewith to form the hybridomas
of interest. Subsequently, procedures of sequentially adding an appropriate medium and
removing the supernatant by centrifugation are repeated to remove cell fusion agents or the
like unfavorable for the growth of the hybridomas.
[0044]
The hybridomas thus obtained are cultured in a conventional selective medium, for
example, a HAT medium (medium containing hypoxanthine, aminopterin, and thymidine) for
selection. Culture in the HAT medium is continued for a period (usually, several days to

several weeks) sufficient for the death of cells other than the hybridomas of interest (non-fused
cells). Subsequently, hybridomas producing the antibody of interest are screened for and
cloned as single clones by a conventional limiting dilution method.
[0045]
In addition to such obtainment of the hybridomas by the immunization of non-human
animals with antigens, hybridomas producing human antibodies having the desired activity
(e.g., cell antiproliferative activity) may be obtained by sensitizing human lymphocytes, for
example, EB virus-infected human lymphocytes, with proteins, protein-expressing cells, or
lysates thereof in vitro and fusing the sensitized lymphocytes with human-derived myeloma
cells capable of dividing permanently, for example, U266 (Accession No. TIB 196).
[0046]
The monoclonal antibody-producing hybridomas thus prepared can be subcultured in a
conventional medium and can also be stored for a long period in liquid nitrogen.
[0047]
Specifically, the desired antigens or cells expressing the desired antigens are used as
sensitizing antigens in immunization according to a conventional immunization method. The
obtained immunocytes are fused with parent cells known in the art according to a conventional
cell fusion method. Monoclonal antibody-producing cells (hybridomas) can be screened for
by a conventional screening method to prepare the antibody of interest.
[0048]
In this context, for example, KM mice (Kirin Pharma Co., Ltd./Medarex) and Xeno
mice (Amgen Inc.) are known as the human antibody-producing mice (e.g., International
Publication Nos. WO02/43478 and WO02/092812). Complete human polyclonal antibodies
can be obtained from the blood of such mice immunized with CAPRIN-1 proteins or
fragments thereof. Alternatively, spleen cells may be isolated from the mice thus immunized
and fused with myeloma cells. In this way, human monoclonal antibodies can be obtained.
[0049]

The antigens can be prepared according to, for example, a method using animal cells
(JP Patent Publication (Kohyo) No. 2007-530068) or a method using baculovirus (e.g.,
International Publication No. W098/46777). Antigens having low immunogenicity can be
bound to immunogenic macromolecules such as albumin for immunization.
[0050]
Alternatively, recombinant antibodies may be used, which are produced using a gene
recombination technique which involves: cloning the antibody genes from hybridomas;
incorporating the antibody genes into appropriate vectors; and introducing the vectors into
hosts (see, e.g., Carl, A.K. Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL
ANTIBODIES, Published in the United Kingdom by MACMILLAN PUBLISHERS LTD,
1990). Specifically, cDNAs of the antibody variable region (V region) are synthesized from
the mRNAs of hybridomas using reverse transcriptase. After obtainment of DNAs encoding
the antibody V regions of interest, the DNAs are ligated with DNAs encoding the desired
antibody constant regions (C regions). The resulting ligation products are then incorporated
into expression vectors. Alternatively, the antibody V region-encoding DNAs may be
incorporated into expression vectors containing antibody C region DNAs. These DNAs are
incorporated into the expression vectors so as to be expressed under the control of expression
control regions, for example, an enhancer and a promoter. Next, host cells can be
transformed with the resulting expression vectors and allowed to express antibodies.
[0051]
The anti-CAPRIN-1 antibody of the present invention is a monoclonal antibody. The
monoclonal antibody includes human monoclonal antibodies, non-human animal monoclonal
antibodies (e.g., mouse, rat, rabbit, and chicken monoclonal antibodies), chimeric monoclonal
antibodies, and the like. The monoclonal antibody may be prepared by the culture of
hybridomas obtained by the fusion between spleen cells from non-human animals (e.g., mice
or human antibody-producing mice, chickens, and rabbits) immunized with CAPRIN-1
proteins and myeloma cells. The chimeric antibody is an antibody prepared from a
combination of sequences derived from different animals and is, for example, an antibody

composed of variable regions of mouse antibody heavy and light chains and heavy and light
chain constant regions of human antibody. The chimeric antibody can be prepared using a
method known in the art which involves, for example: ligating DNAs encoding antibody V
regions with DNAs encoding human antibody C regions; incorporating the resulting ligation
products into expression vectors; and introducing the vectors into hosts so that antibodies are
produced. In Examples described later, human-mouse chimeric monoclonal antibody was
prepared and the antitumor effect thereof was confirmed. These monoclonal antibodies
comprise a heavy chain variable (VH) region having the amino acid sequence of SEQ ID NO:
8 and a light chain variable (VL) region having the amino acid sequence of SEQ ID NO: 12,
wherein the VH region comprises CDR1 represented by the amino acid sequence of SEQ ID
NO: 5, CDR2 represented by the amino acid sequence of SEQ ID NO: 6, and CDR3
represented by the amino acid sequence of SEQ ID NO: 7, and the VL region comprises
CDR1 represented by the amino acid sequence of SEQ ID NO: 9, CDR2 represented by the
amino acid sequence of SEQ ID NO: 10, and CDR3 represented by the amino acid sequence
of SEQ ID NO: 11.
[0052]
The humanized antibody, also called reshaped human antibody, is an engineered
antibody. The humanized antibody is constructed by grafting human antibody
complementarity determining regions with antibody CDRs derived from an immunized animal.
A general gene recombination approach therefor is also known.
[0053]
Specifically, for example, DNA sequences designed so as to link mouse and chicken
antibodies CDRs and human antibody framework regions (FRs) are synthesized by PCR using
several prepared oligonucleotides having terminal portions overlapping with each other. The
obtained DNAs are ligated with DNAs encoding human antibody constant regions.
Subsequently, the resulting ligation products are incorporated into expression vectors, which
are then introduced into hosts for antibody production to obtain the antibody of interest (see
European Patent Application Publication No. EP239400 and International Publication No.

WO96/02576). The human antibody FRs connected via CDRs are selected such that the
CDRs form a favorable antigen-binding site. If necessary, amino acids in the framework
regions of antibody variable regions may be substituted so that the CDRs of the resulting
reshaped human antibody form an appropriate antigen-binding site (Sato K. et al., Cancer
Research 1993, 53: 851-856). In addition, these framework regions may be replaced with
framework regions derived from various human antibodies (see International Publication No.
W099/51743).
[0054]
The human antibody framework regions connected via CDRs are selected such that the
CDRs form a favorable antigen-binding site. If necessary, amino acids in the framework
regions of antibody variable regions may be substituted such that the CDRs of the resulting
reshaped human antibody form an appropriate antigen-binding site (Sato K. et al., Cancer
Research 1993, 53: 851-856).
[0055]
Amino acids in variable regions (e.g., FRs) or constant regions of the chimeric antibody
or the humanized antibody thus prepared may be substituted by other amino acids.
[0056]
The amino acid substitution is the substitution of, for example, less than 15, less than
10, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less amino acids,
preferably 1 to 5 amino acids, more preferably 1 or 2 amino acids. The substituted antibody
should be functionally equivalent to an unsubstituted antibody. The substitution is desirably
conservative amino acid substitution, which is the substitution between amino acids similar in
properties such as charge, side chains, polarity, and aromaticity. The amino acids can be
classified in terms of similar properties into, for example: basic amino acids (arginine, lysine,
and histidine); acidic amino acids (aspartic acid and glutamic acid); uncharged polar amino
acids (glycine, asparagine, glutamine, serine, threonine, cysteine, and tyrosine); nonpolar
amino acids (leucine, isoleucine, alanine, valine, proline, phenylalanine, tryptophan, and

methionine); branched amino acids (leucine, valine, and isoleucine); and aromatic amino acids
(phenylalanine, tyrosine, tryptophan, and histidine).
[0057]
Examples of modified antibodies can include antibodies bound with various molecules
such as polyethylene glycol (PEG). In the modified antibody of the present invention, the
substance to be bound is not limited. In order to obtain such a modified antibody, the
obtained antibody can be chemically modified. A method therefor has already been
established in the art.
[0058]
In this context, the phrase "functionally equivalent" means that an antibody concerned
has biological or biochemical activity similar to that of the antibody of the present invention,
specifically, the antibody concerned has the function of damaging tumor and essentially causes
no rejection when applied to humans, for example. Examples of such activity can include
antiproliferative activity and binding activity.
[0059]
A method for preparing a polypeptide functionally equivalent to a certain polypeptide,
which involves introducing a mutation into a polypeptide, is well known to those skilled in the
art. For example, those skilled in the art can appropriately introduce a mutation into the
antibody of the present invention using site-directed mutagenesis (Hashimoto-Gotoh, T. et al.,
(1995) Gene 152: 271-275; Zoller, MJ., and Smith, M. (1983) Methods Enzymol., 100: 468-
500; Kramer, W. et al., (1984) Nucleic Acids Res., 12: 9441-9456; Kramer, W. and Fritz, HI,
(1987) Methods Enzymol., 154: 350-367; Kunkel, TA., (1985) Proc. Natl. Acad. Sci. USA.,
82: 488-492; and Kunkel (1988) Methods Enzymol., 85: 2763-2766) or the like, thereby
prepare an antibody functionally equivalent to the antibody of the present invention.
[0060]
An antibody that recognizes an epitope of a CAPRIN-1 protein recognized by each
anti-CAPRIN-1 antibody described above can be obtained by a method generally known to
those skilled in the art. For example, the antibody can be obtained by a method which

involves determining the epitope of the CAPRIN-1 protein recognized by the anti-CAPRIN-1
antibody by a conventional method (e.g., epitope mapping) and preparing an antibody using a
polypeptide having an amino acid sequence contained in the epitope as an immunogen, or a
method which involves determining an epitope for an antibody prepared by a conventional
method and selecting an antibody that recognizes the same epitope as that for the anti-
CAPRIN-1 antibody. In this context, the "epitope" refers to a polypeptide fragment having
antigenicity or immunogenicity in mammals, preferably humans. Its smallest unit consists of
approximately 7 to 12 amino acids, preferably 8 to 11 amino acids.
[0061]
The antibody of the present invention has an affinity constant Ka (kon/koff) of preferably
at least 107 M"1, at least 108 M"1, at least 5 x 108 M"1, at least 109 M"1, at least 5 x 109 M"1, at
least 1010 M'1, at least 5 x 1010 M"1, at least 1011 M"1, at least 5 x 1011 M"1, at least 1012 M"1, or
at least 1013 M"1.
[0062]
The antibody of the present invention can be conjugated with an antitumor agent. The
conjugation of the antibody with the antitumor agent can be performed via a spacer having a
group (e.g., a succinimidyl group, a formyl group, a 2-pyridyldithio group, a maleimidyl group,
an alkoxycarbonyl group, or a hydroxy group) reactive with an amino group, a carboxyl group,
a hydroxy group, a thiol group, or the like.
[0063]
Examples of the antitumor agent include the following antitumor agents publicly
known in literatures, etc.: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide,
methotrexate, 5-fluorouracil, thiotepa, busulfan, improsulfan, piposulfan, benzodopa,
carboquone, meturedopa, uredopa, altretamine, triethylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine, bullatacin,
bullatacinone, camptothecin, bryostatin, callystatin, cryptophycin 1, cryptophycin 8, dolastatin,
duocarmycin, eleutherobin, pancratistatin, sarcodictyin, spongistatin, chlorambucil,
chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine,

mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine,
trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, lomustine, nimustine,
ranimustine, calicheamicin, dynemicin, clodronate, esperamicin, aclacinomycin, actinomycin,
authramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin,
chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, Adriamycin, epirubicin,
esorubicin, idarubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin,
olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate,
fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine,
carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens (e.g.,
calusterone, dromostanolone propionate, epitiostanol, mepitiostane, and testolactone),
aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone, aldophosphamide glycoside,
aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatraxate, defofamine,
demecolcine, diaziquone, elfornithine, elliptinium acetate, epothilone, etoglucid, lentinan,
lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerine,
pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide,
procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium, tenuazonic acid, triaziquone,
roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol,
mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine,
mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine, etoposide, ifosfamide,
mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin,
aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase inhibitors,
difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically acceptable
salts and derivatives thereof.
[0064]
Alternatively, the antibody of the present invention can be administered in combination
with an antitumor agent to produce a higher therapeutic effect. This approach is adaptable to
a patient with cancer expressing CAPRIN-1 either before or after surgical operation. This

approach can be applied, particularly after surgery, to CAPRIN-1 -expressing cancer, which
has been treated conventionally with an antitumor agent alone, to produce higher prevention of
cancer recurrence or prolongation of survival time.
[0065]
Examples of the antitumor agent used in the combined administration with the antibody
of the present invention include the following antitumor agents publicly known in literatures,
etc.: paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fiuorouracil,
thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturedopa, uredopa,
altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide,
trimethylolomelamine, bullatacin, bullatacinone, camptothecin, bryostatin, callystatin,
cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eleutherobin, pancratistatin,
sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cholophosphamide, estramustine,
ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin,
phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin,
fotemustine, lomustine, nimustine, ranimustine, calicheamicin, dynemicin, clodronate,
esperamicin, aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin,
carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-
oxo-L-norleucine, Adriamycin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin
C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin,
quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin,
zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine,
thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol,
mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, frolinic acid, aceglatone,
aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene,
edatraxate, defofamine, demecolcine, diaziquone, elfornithine, elliptinium acetate, epothilone,
etoglucid, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone,
mopidanmol, nitraerine, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid,

2-ethylhydrazide, procarbazine, razoxane, rhizoxin, schizophyllan, spirogermanium,
tenuazonic acid, triaziquone, roridin A, anguidine, urethane, vindesine, dacarbazine,
mannomustine, mitobronitol, mitolactol, pipobroman, gacytosine, docetaxel, chlorambucil,
gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine,
etoposide, ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide,
edatrexate, daunomycin, aminopterin, Xeloda, ibandronate, irinotecan, topoisomerase
inhibitors, difluoromethylornithine (DMFO), retinoic acid, capecitabine, and pharmaceutically
acceptable salts (known in the art) and derivatives (known in the art) thereof. Of these
antitumor agents, cyclophosphamide, paclitaxel, docetaxel, or vinorelbine is particularly
preferably used.
[0066]
Alternatively, the antibody of the present invention may be bound to a radioisotope
publicly known in literatures, etc., such as 211At, 131I, 1251,90Y, 186Re, I88Re, 153Sm, 212Bi, 32P,
175Lu, or 176Lu. Desirably, a radioisotope effective for the treatment or diagnosis of tumor is
used.
[0067]
The antibody of the present invention is an antibody having immunological reactivity
with CAPRIN-1, an antibody specifically recognizing CAPRIN-1, or an antibody specifically
binding to CAPRIN-1 and exhibits cytotoxic activity or antiproliferative effect on cancer.
The antibody preferably should have a structure that causes little or no rejection in recipient
animals. Examples of such antibodies include human antibodies, humanized antibodies,
chimeric antibodies (e.g., human-mouse chimeric antibodies), single-chain antibodies, and
bispecific antibodies when the recipient animals are humans. These antibodies (1) have
variable regions of heavy and light chains derived from a human antibody, (2) have variable
regions with CDRs (CDR1, CDR2, and CDR3) of heavy and light chains derived from a non-
human animal antibody and framework regions derived from a human antibody, or (3) these
antibodies are recombinant antibodies having variable regions of heavy and light chains
derived from a non-human animal antibody and heavy and light chain constant regions derived

from a human antibody. The antibody of the present invention is preferably the former two
antibodies.
[0068]
Such recombinant antibodies can be prepared as follows: DNAs encoding monoclonal
antibodies (e.g., human, mouse, rat, rabbit, and chicken monoclonal antibodies) against human
CAPRIN-1 are cloned from antibody-producing cells such as hybridomas and used as
templates in RT-PCR or the like to prepare DNAs encoding the variable regions of the light
and heavy chains in the antibodies. The respective sequences of the variable regions of the
light and heavy chains and the respective sequences of CDR1, CDR2, and CDR3 in each
region are determined on the basis of the Kabat EU numbering system (Kabat et al., Sequences
of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institute of
Health, Bethesda, Md. (1991)).
[0069]
Such a DNA encoding each variable region or a DNA encoding each CDR is prepared
using a gene recombination technique (Sambrook et al., Molecular Cloning A Laboratory
Manual, Cold Spring Harbor Laboratory Press (1989)) or a DNA synthesizer. In this context,
the human monoclonal antibody-producing hybridomas can be prepared by immunizing
human antibody-producing animals (e.g., mice) with human CAPRIN-1 and then fusing spleen
cells excised from the immunized animals with myeloma cells. Aside from this, DNAs
encoding light or heavy chain variable and constant regions derived from human antibody are
prepared, if necessary, using a gene recombination technique or a DNA synthesizer.
[0070]
For the humanized antibody, DNAs in which the CDR coding sequences in DNAs
encoding a human antibody-derived light or heavy chain variable regions are substituted by
corresponding CDR coding sequences of a non-human animal (e.g., mouse, rat, rabbit, or
chicken)-derived antibody can be prepared and ligated with the DNAs encoding human
antibody-derived light or heavy chain constant regions to prepare a DNA encoding the
humanized antibody.

[0071]
For the chimeric antibody, DNAs encoding light or heavy chain variable regions of a
non-human animal (e.g., mouse, rat, rabbit, or chicken)-derived antibody can be ligated with
DNAs encoding human antibody-derived light or heavy chain constant regions to prepare a
DNA encoding the chimeric antibody.
[0072]
The single-chain antibody refers to an antibody comprising heavy and light chain
variable regions linearly linked to each other via a linker. A DNA encoding the single-chain
antibody can be prepared by ligating a DNA encoding the heavy chain variable region, a DNA
encoding the linker, and a DNA encoding the light chain variable region. In this context, the
heavy and light chain variable regions are both derived from a human antibody or derived
from a human antibody having CDRs alone substituted by CDRs of a non-human animal (e.g.,
mouse, rat, rabbit, or chicken)-derived antibody. The linker consists of 12 to 19 amino acids.
Examples thereof include (G4S)3 consisting of 15 amino acids (G.B. Kim et al., Protein
Engineering Design and Selection 2007, 20 (9): 425-432).
[0073]
The bispecific antibody (diabody) refers to an antibody capable of specifically binding
to two different epitopes. A DNA encoding the bispecific antibody can be prepared by
ligating, for example, a DNA encoding a heavy chain variable region A, a DNA encoding a
light chain variable region B, a DNA encoding a heavy chain variable region B, and a DNA
encoding a light chain variable region A in this order (provided that the DNA encoding a light
chain variable region B and the DNA encoding a heavy chain variable region B are ligated via
a DNA encoding a linker as described above). In this context, the heavy and light chain
variable regions are all derived from a human antibody or derived from a human antibody
having CDRs alone substituted by CDRs of a non-human animal (e.g., mouse, rat, rabbit, or
chicken)-derived antibody.
[0074]

The recombinant DNAs thus prepared can be incorporated into one or more appropriate
vectors, which are then introduced into host cells (e.g., mammalian cells, yeast cells, and
insect cells) so that the DNAs are (co)expressed to produce recombinant antibodies (P.J.
Delves., ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES., 1997 WILEY, P.
Shepherd and C. Dean., Monoclonal Antibodies., 2000 OXFORD UNIVERSITY PRESS; and
J.W. Goding., Monoclonal Antibodies: principles and practice., 1993 ACADEMIC PRESS).
[0075]
Examples of the antibody of the present invention prepared by any of the methods
described above include the following antibody (a) obtained in Examples described later:
[0076]
(a) an antibody comprising a heavy chain variable region comprising amino acid
sequences of SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid
sequences of SEQ ID NOs: 9, 10, and 11 (e.g., an antibody composed of a heavy chain
variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO: 12).
[0077]
In this context, the amino acid sequences represented by SEQ ID NOs: 5, 6, and 7
correspond to CDR1, CDR2, and CDR3, respectively, of a mouse antibody heavy chain
variable region. The amino acid sequences represented by SEQ ID NOs: 9, 10, and 12
correspond to CDR1, CDR2, and CDR3, respectively, of a mouse antibody light chain variable
region.
[0078]
Examples of the humanized antibody, the chimeric antibody, the single-chain antibody,
or the bispecific antibody of the present invention include the following antibodies:
[0079]
(i) an antibody or the fragment thereof comprising a heavy chain variable region
comprising the amino acid sequences of SEQ ID NOs: 6, 7, and 8 and the amino acid
sequences of framework regions derived from human antibody and a light chain variable

region comprising the amino acid sequences of SEQ ID NOs: 9,10, and 11 and the amino acid
sequences of framework regions derived from human antibody;
[0080]
(ii) an antibody or the fragment thereof comprising a heavy chain variable region
comprising the amino acid sequences of SEQ ID NOs: 5, 6, and 7 and the amino acid
sequences of framework regions derived from human antibody, a heavy chain constant region
comprising an amino acid sequence derived from human antibody, a light chain variable
region comprising the amino acid sequences of SEQ ID NOs: 9, 10, and 11 and the amino acid
sequences of framework regions derived from human antibody, and a light chain constant
region comprising an amino acid sequence derived from human antibody; and
[0081]
(iii) an antibody or the fragment thereof comprising a heavy chain variable region
comprising the amino acid sequence of SEQ ID NO: 8, a heavy chain constant region
comprising an amino acid sequence derived from human antibody, a light chain variable
region comprising the amino acid sequence of SEQ ID NO: 12, and a light chain constant
region comprising an amino acid sequence derived from human antibody.
[0082]
The sequences of the constant and variable regions of human antibody heavy and light
chains are available from, for example, NCBI (USA; GenBank, UniGene, etc.). For example,
the following sequences can be referred to: Accession No. J00228 for a constant region of a
human IgGl heavy chain; Accession No. J00230 for a constant region of a human IgG2 heavy
chain; Accession No. X03604 for a constant region of a human IgG3 heavy chain; Accession
No. K01316 for a constant region of a human IgG4 heavy chain; Accession Nos. V00557,
X64135, and X64133 for a constant region of a human K light chain; and Accession Nos.
X64132 and X64134 for a constant region of a human X light chain.
[0083]
Preferably, these antibodies have cytotoxic activity and can thereby exert an antitumor
effect.

[0084]
The above particular sequences of the variable regions and CDRs of heavy and light
chains in each antibody are provided merely for illustrative purposes. It is obvious that the
antibody of the present invention is not limited by the particular sequences. Hybridomas
capable of producing anti-human CAPRIN-1 human antibodies or non-human animal
antibodies (e.g., mouse antibodies) different from those described above are prepared, and
monoclonal antibodies produced by the hybridomas are recovered and assessed as being (or
being not) the antibodies of interest with immunological binding activity against human
CAPRIN-1 and cytotoxic activity as indexes. The monoclonal antibody-producing
hybridomas of interest are thereby identified. Then, DNAs encoding variable regions heavy
and light chains of the in antibodies of interest are produced from the hybridomas and
sequenced, as described above. The DNAs are used for the preparation of the different
antibodies.
[0085]
The antibody of the present invention may be the antibody (a) having the substitution,
deletion, or addition of one or several amino acids, particularly in a sequence of a framework
region and/or a constant region, as long as the antibody has such specificity that it can
specifically recognize CAPRIN-1. In this context, the term "several" means preferably 2 to 5,
more preferably 2 or 3.
[0086]
The present invention further provides a DNA encoding the antibody of the present
invention, a DNA encoding the heavy or light chain of the antibody, or a DNA encoding the
variable region of the heavy or light chain in the antibody. Such a DNA includes, for
example, a DNA encoding a heavy chain variable region which comprises nucleotide
sequences encoding the amino acid sequences represented by SEQ ID NOs: 5, 6, and 7, and a
DNA encoding a light chain variable region which comprises nucleotide sequences encoding
the amino acid sequences represented by SEQ ID NOs: 9, 10, and 11, in the case of the
antibody (a).

[0087]
The CDRs encoded by the DNA having these sequences serve as regions that
determine the specificity of the antibody. Sequences encoding the other regions (i.e.,
constant regions and framework regions) of the antibody may therefore be sequences derived
from other antibodies. In this context, "other antibodies" also include antibodies derived
from non-human organisms and are preferably those derived from humans from the viewpoint
of reducing side effects. Specifically, the DNA of the present invention preferably comprises
nucleotide sequences encoding corresponding human antibody-derived amino acid sequences
of regions encoding each framework region and each constant region in the heavy and light
chains.
[0088]
Further examples of the DNA encoding the antibody of the present invention include a
DNA encoding a heavy chain variable region which comprises a nucleotide sequence
encoding the amino acid sequence of SEQ ID NO: 8, and a DNA encoding a light chain
variable region which comprises a nucleotide sequence encoding the amino acid sequence of
SEQ ID NO: 12. In this context, the nucleotide sequence encoding the amino acid sequence
of SEQ ID NO: 8 is, for example, the nucleotide sequence of SEQ ID NO: 13. The
nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 12 is, for example, the
nucleotide sequence of SEQ ID NO: 14. For these DNAs, it is preferred that a region
encoding each constant region in the heavy and light chains should comprise a nucleotide
sequence encoding a corresponding amino acid sequence derived from human antibody.
[0089]
These antibody DNAs can be obtained, for example, by the methods described above
or the following method: first, total RNAs are prepared from hybridomas related to the
antibody of the present invention using a commercially available RNA extraction kit, and
cDNAs are synthesized using reverse transcriptase and random primers or the like.
Subsequently, the antibody-encoding cDNAs are amplified by PCR using oligonucleotide
primers for conserved sequences of each variable region in known mouse antibody heavy and

light chain genes. Sequences encoding the constant regions can be obtained by the PCR
amplification of known sequences. The nucleotide sequence of the DNA can be incorporated
into a plasmid or a phage for sequencing, for example, and determined according to a routine
method.
[0090]
The antitumor effect of the anti-CAPRIN-1 antibody used in the present invention on
CAPRIN-1 -expressing cancer cells seems to be brought about by the following mechanism:
[0091]
The effector cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and
complement-dependent cytotoxicity (CDC) against the CAPRIN-1-expressing cells seems to
be brought.
[0092]
The antitumor effect based on the mechanism is known to correlate with the number of
antibody-binding target molecules expressed on the surface of cancer cells (Niwa R., Clinical
Cancer Research 2005 Mar 15; 11 (6): 2327-2336). The number of target molecules
expressed on the surface of cancer cells can be examined using an existing assay kit capable of
measuring the number of molecules on cell surface. Specifically, the number of antibody-
binding target molecules can be determined by: reacting cancer cells with, for example,
antibodies against the target molecules as primary antibodies; reacting therewith fluorescently
labeled antibodies against the primary antibodies, together with calibration curve beads with
the preliminarily known number of molecules; measuring the mean fluorescence intensity of
the samples; and determining the number of the target molecules on the basis of the obtained
calibration curve.
[0093]
Thus, the anti-CAPRIN-1 antibody used in the present invention can be evaluated for
its activity by determining ex vivo the ADCC activity or the CDC activity against CAPRIN-1 -
expressing cancer cells or by examining the number of CAPRIN-1 molecules expressed on the

surface of cancer cells in the case of using the anti-CAPRIN-1 antibody according to the
present invention as a primary antibody as specifically shown below in Examples.
[0094]
The anti-CAPRIN-1 antibody used in the present invention binds to CAPRIN-1
proteins on cancer cells and exhibits an antitumor effect through the activity. Thus, the anti-
CAPRIN-1 antibody of the present invention is presumably useful in the treatment or
prevention of cancer. Specifically, the present invention provides a pharmaceutical
composition for treatment and/or prevention of cancer, comprising the anti-CAPRIN-1
antibody as an active ingredient. The anti-CAPRIN-1 antibody used for the purpose of
administration to human bodies (antibody therapy) is preferably a human antibody or a
humanized antibody for reducing immunogenicity.
[0095]
The anti-CAPRIN-1 antibody with higher binding affinity for a CAPRIN-1 protein on
cancer cell surface exerts stronger antitumor activity. Thus, a stronger antitumor effect can
be expected if the anti-CAPRIN-1 antibody having high binding affinity for the CAPRIN-1
protein can be obtained. Such an antibody is adaptable to a pharmaceutical composition
intended for the treatment and/or prevention of cancer. Desirably, such high binding affinity
is preferably at least 107 M"1, at least 108 M"1, at least 5 x 108 M"1, at least 109 M"1, at least 5 x
109 M"1, at least 1010 M"1, at least 5 x 1010 M"1, at least 10u M"1, at least 5 x 1011 M"1, at least
1012 M"1, or at least 1013 M"1, in terms of an association constant (affinity constant) Ka
(kon/koff), as described above.
[0096]
The binding of anti-CAPRIN-1 antibodies to a larger number of CAPRIN-1 molecules
on cancer cell surface produces stronger antitumor activity. Desirably, the number of
CAPRIN-1 molecules to which the antibodies bind for the expected antitumor effect is 104 or
more, preferably 105 or more CAPRTN-1 molecules per cancer cell measured using the anti-
CAPRIN-1 antibody of the present invention.
[0097]

The ability of the antibody to bind to CAPRIN-1 can be determined by use of binding
assay using, for example, ELISA, Western blot, immunofluorescence, and flow cytometry
analysis, as described in Examples.
[0098]

The antibody that recognizes CAPRIN-1 can be tested for its reactivity with CAPRIN-1
by an immunohistochemical method well known to those skilled in the art using a
paraformaldehyde- or acetone-fixed frozen section or paraformaldehyde-fixed paraffin-
embedded section of a tissue obtained from a patient during surgical operation or from an
animal carrying a xenograft tissue inoculated with a cell line expressing CAPRIN-1 either
spontaneously or after transfection.
[0099]
For immunohistochemical staining, the antibody reactive with CAPRIN-1 can be
stained by various methods. For example, the antibody can be visualized through reaction
with a horseradish peroxidase-conjugated goat anti-mouse antibody, goat anti-rabbit antibody
or goat anti-chicken antibody.
[0100]
Pharmaceutical composition>
A target of the pharmaceutical composition for treatment and/or prevention of cancer of
the present invention is not particularly limited as long as the target is cancer (cells) expressing
a CAPRIN-1 gene.
[0101]
The terms "tumor" and "cancer" used herein mean malignant neoplasm and are used
interchangeably with each other.
[0102]
The cancer targeted in the present invention is cancer expressing a CAPRIN-1 protein-
encoding gene and is preferably breast cancer, kidney cancer, pancreatic cancer, large bowel

cancer, lung cancer, brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate
cancer, urinary bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma,
mastocytoma, or melanoma.
[0103]
Specific examples of these cancers include, but not limited to, breast adenocarcinoma,
complex-type breast adenocarcinoma, malignant mixed tumor of mammary gland, intraductal
papillary adenocarcinoma, lung adenocarcinoma, squamous cell cancer, small-cell cancer,
large-cell cancer, glioma which is tumor of neuroepithelial tissue, ependymoma, neuronal
tumor, embryonal neuroectodermal tumor, neurilemmoma, neurofibroma, meningioma,
chronic lymphocytic leukemia, lymphoma, gastrointestinal lymphoma, alimentary lymphoma,
small to medium cell-type lymphoma, cecal cancer, ascending colon cancer, descending colon
cancer, transverse colon cancer, sigmoid colon cancer, rectal cancer, epithelial ovarian cancer,
germ cell tumor, stromal cell tumor, pancreatic ductal carcinoma, invasive pancreatic ductal
carcinoma, pancreatic adenocarcinoma, acinar cell carcinoma, adenosquamous carcinoma,
giant cell tumor, intraductal papillary-mucinous neoplasm, mucinous cystic neoplasm,
pancreatoblastoma, serous cystadenocarcinoma, solid-pseudopapillary tumor, gastrinoma,
glucagonoma, insulinoma, multiple endocrine neoplasia type-1 (Wermer's syndrome),
nonfunctional islet cell tumor, somatostatinoma, and VIPoma.
[0104]
The test subject as the recipient are preferably mammals, for example, mammals
including primates, pet animals, livestock, and sport animals and are particularly preferably
humans, dogs, and cats.
[0105]
In the case of using the antibody of the present invention as a pharmaceutical
composition, the pharmaceutical composition can be formulated by a method generally known
to those skilled in the art. For example, the pharmaceutical composition can be used in the
form of a parenteral injection of an aseptic solution or suspension with water or any other
pharmaceutically acceptable liquid. For example, the pharmaceutical composition may be

formulated with the antibody mixed in a unit dosage form required for generally accepted
pharmaceutical practice, in appropriate combination with pharmacologically acceptable
carriers or media, specifically, sterilized water, physiological saline, plant oil, an emulsifier, a
suspending agent, a detergent, a stabilizer, a flavoring agent, an excipient, a vehicle, a
preservative, a binder, etc. The amount of the active ingredient in such a preparation is
determined so that an appropriate dose within the prescribed range can be achieved.
[0106]
An aseptic composition for injection can be formulated according to conventional
pharmaceutical practice using a vehicle such as injectable distilled water.
[0107]
Examples of aqueous solutions for injection include physiological saline, isotonic
solutions containing glucose and other adjuvants, for example, D-sorbitol, D-mannose, D-
mannitol, and sodium chloride. These solutions may be used in combination with an
appropriate solubilizer, for example, an alcohol (specifically, ethanol) or a polyalcohol (e.g.,
propylene glycol and polyethylene glycol), or a nonionic detergent, for example, polysorbate
80(TM)orHCO-60.
[0108]
Examples of oily solutions include sesame oil and soybean oil. These solutions may
be used in combination with a solubilizer such as benzyl benzoate or benzyl alcohol. The
solutions may be further mixed with a buffer (e.g., a phosphate buffer solution and a sodium
acetate buffer solution), a soothing agent (e.g., procaine hydrochloride), a stabilizer (e.g.,
benzyl alcohol and phenol), and an antioxidant. The injection solutions thus prepared are
usually charged into appropriate ampules.
[0109]
The pharmaceutical composition of the present invention is administered orally or
parenterally, preferably parenterally. Specific examples of its dosage forms include
injections, intranasal administration agents, transpulmonary administration agents, and
percutaneous administration agents. Examples of the injections include intravenous injection,

intramuscular injection, intraperitoneal injection, and subcutaneous injection, through which
the pharmaceutical composition can be administered systemically or locally.
[0110]
Also, the administration method can be appropriately selected depending on the age,
weight, sex, symptoms, etc. of a patient. The dose of a pharmaceutical composition
containing the antibody or a polynucleotide encoding the antibody can be selected within a
range of, for example, 0.0001 to 1000 mg/kg of body weight per dose. Alternatively, the
dose can be selected within a range of, for example, 0.001 to 100000 mg/body of a patient,
though the dose is not necessarily limited to these numeric values. Although the dose and the
administration method vary depending on the weight, age, sex, symptoms, etc. of a patient,
those skilled in the art can appropriately select the dose and the method.
[0111]
The pharmaceutical composition including the antibody or fragments thereof of the
present invention can be administered to a test subject to treat and/or prevent cancer,
preferably breast cancer, kidney cancer, pancreatic cancer, large bowel cancer, lung cancer,
brain tumor, gastric cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary
bladder cancer, esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or
melanoma.
[0112]
The present invention further encompasses a method for treating and/or preventing
cancer, comprising administering the pharmaceutical composition of the present invention in
combination with the antitumor agent as exemplified above or a pharmaceutical composition
comprising the antitumor agent to a test subject. The antibody or the fragment thereof of the
present invention may be administered simultaneously with or separately from the antitumor
agent to the test subject. In the case of separately administering these pharmaceutical
compositions, either one may be administered first or later. Their dosing intervals, doses,
administration routes, and the number of doses can be appropriately selected by a specialist.
The dosage forms of separate drugs to be administered simultaneously also include, for

example, pharmaceutical compositions each formulated by mixing the antibody or the
fragment thereof of the present invention and the antitumor agent into a pharmacologically
acceptable carrier (or medium). The above descriptions about prescription, formulation,
administration routes, doses, cancer, etc. as to the pharmaceutical compositions and dosage
forms containing the antibody of the present invention are also applicable to any of the above-
described pharmaceutical compositions and dosage forms containing the antitumor agent.
[0113]
Thus, the present invention also provides a pharmaceutical combination for treatment
and/or prevention of cancer, comprising the pharmaceutical composition of the present
invention and a pharmaceutical composition comprising the antitumor agent as exemplified
above. The present invention also provides a pharmaceutical composition for treatment
and/or prevention of cancer, comprising the antibody or the fragment thereof of the present
invention and the antitumor agent together with a pharmacologically acceptable carrier.
[0114]

The present invention further provides the following polypeptides and DNAs related to
the antibody (a):
(i) a polypeptide comprising the amino acid sequences of SEQ ID NOs: 8 and 12, and a
DNA encoding the polypeptide, for example, a DNA comprising the nucleotide sequences of
SEQ ID NOs: 13 and 14;
(ii) a heavy chain CDR polypeptide selected from the group consisting of amino acid
sequences of SEQ ID NOs: 5, 6, and 7, and a DNA encoding the polypeptide; and
(iii) a light chain CDR polypeptide selected from the group consisting of amino acid
sequences of SEQ ID NOs: 9, 10, and 11, and a DNA encoding the polypeptide.
[0115]
These polypeptides and DNAs can be prepared using gene recombination techniques as
described above.
[0116]

The aspects of the present invention described above are summarized below.
(1) An antibody or a fragment thereof which has immunological reactivity with a
CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable
region comprising CDRs of SEQ ID NOs: 5, 6, and 7 and a light chain variable region
comprising CDRs of SEQ ID NOs: 9,10, and 11.
(2) The antibody or the fragment thereof according to (1), wherein the antibody is a
human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a
bispecific antibody.
(3) The antibody or the fragment thereof according to (1) or (2), wherein the antibody
or the fragment thereof is conjugated with an antitumor agent.
(4) A pharmaceutical composition for treatment and/or prevention of cancer,
comprising an antibody or a fragment thereof according to any of (1), (2) or (3) as an active
ingredient.
(5) The pharmaceutical composition according to (4), wherein the cancer is breast
cancer, kidney cancer, pancreatic cancer, large bowel cancer, lung cancer, brain tumor, gastric
cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer,
esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
(6) A pharmaceutical combination for treatment and/or prevention of cancer,
comprising a pharmaceutical composition according to (4) or (5) and a pharmaceutical
composition comprising an antitumor agent.
(7) A DNA encoding an antibody or a fragment thereof according to (1) or (2).
(8) A method for treating and/or preventing cancer, comprising administering an
antibody or a fragment thereof according to any of (1) to (3), a pharmaceutical composition
according to (4) or (5), or a pharmaceutical combination according to (6) to a test subject.
Examples
[0117]

Hereinafter, the present invention will be described specifically with reference to
Examples. However, the scope of the present invention is not intended to be limited by these
specific examples.
[0118]
Analysis of CAPRIN-1 gene expression in each tissue
Gene expression of CAPRIN-1 in canine and human normal tissues and various cell
lines was examined by RT-PCR according to Example 1(4) described in WO2010/016526.
As a result, strong expression was obeserved in the testis among the healthy canine tissues,
whereas expression was obeserved in canine breast cancer and adenocarcinoma tissues. As a
result of also confirming the expression in human tissues, the expression was confirmed only
in the testis among normal tissues, as with the canine CAPRIN-1 gene. By contrast, the
expression was detected in many types of cancer cell lines, including 8 human breast cancer
cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-20, MDA-MB-231V, and
MRK-nu-1) and 4 pancreatic cancer cell lines (Capan-2, MIAPaCa-2, Panc-1, and BxPc-3),
among cancer cells. These results demonstrated that CAPRIN-1 is expressed in various
cancer cells, though its expression is not seen in normal tissues other than the testis.
[0119]
Preparation of mouse monoclonal antibody against CAPRIN-1
100 [xg of human CAPRIN-1 proteins having the amino acid sequence of SEQ ID NO:
2, which were prepared in Example 3 described in WO2010/016526, was mixed with an equal
amount of MPL+TDM adjuvant (Sigma-Aldrich Corp.). This mixture was used as an antigen
solution per mouse. The antigen solution was intraperitoneally administered to each 6-week-
old Balb/c mouse ( Japan SLC, Inc.). Then, 7 boosters were performed every 1 week to
complete immunization. Three days after the final shot, the spleen of each mouse was
excised and ground between two sterilized glass slides. Procedures of washing with PBS(-)
(Nissui Pharmaceutical Co., Ltd.) and removing the supernatant by centrifugation at 1500 rpm
for 10 minutes were repeated three times to obtain spleen cells. The obtained spleen cells
were mixed with mouse myeloma cells SP2/0 (purchased from ATCC) at a ratio of 10:1. 200

ul of an RPMI1640 medium containing 10% FBS was heated to 37°C and mixed with 800 ul
of PEG 1500 (Boehringer Ingelheim GmbH), and the PEG solution thus prepared was added to
the cell mixture, which was then left standing for 5 minutes for cell fusion. After removal of
the supernatant by centrifugation at 1700 rpm for 5 minutes, the cells were suspended in 150
ml of an RPMI1640 medium containing 15% FBS supplemented with 2% equivalent of a
HAT solution (Life Technologies, Inc/Gibco) (HAT selective medium). This suspension
was inoculated to fifteen 96-well plates (Thermo Fisher Scientific Inc/Nunc) at a
concentration of 100 ul/well. The spleen cells and the myeloma cells were fused by culture
at 37°C for 7 days under conditions of 5% CO2 to obtain hybridomas.
[0120]
The prepared hybridomas were screened with the binding affinity of antibodies
produced by the hybridomas against CAPRIN-1 proteins as an index. One ng/ml solution of
the CAPRIN-1 proteins prepared in Example 3 described in WO2010/016526 was added to a
96-well plate at a concentration of 100 ul/well and left standing at 4°C for 18 hours. Each
well was washed three times with PBS-T. Then, a 0.5% bovine serum albumin (BSA)
solution (Sigma-Aldrich Corp.) was added thereto at a concentration of 400 ul/well and left
standing at room temperature for 3 hours. The solution in each well was discarded, and each
well was washed three times with 400 ul of PBS-T. Then, the culture supernatant of each
hybridoma obtained above was added thereto at a concentration of 100 ul/well and left
standing at room temperature for 2 hours. Each well was washed three times with PBS-T.
Then, HRP-labeled anti-mouse IgG (H+L) antibodies (Invitrogen Corp.) diluted 5000-fold
with PBS were added thereto at a concentration of 100 ul/well and left standing at room
temperature for 1 hour. Each well was washed three times with PBS-T. Then, a TMB
substrate solution (Thermo Fisher Scientific Inc.) was added thereto at a concentration of 100
ul/well and left standing for 15 to 30 minutes to cause color reaction. After the color
development, the reaction was terminated by the addition of 1 N sulfuric acid at a
concentration of 100 ul/well. The absorbance was measured at 450 run and 595 nm using an

absorption spectrometer. As a result, several hybridomas producing antibodies having high
absorbance were selected.
[0121]
The selected hybridomas were added to a 96-well plate at a density of 0.5 cells/well
and cultured in the plate. One week later, hybridomas forming single colonies in the wells
were observed. The cells in these wells were further cultured, and the cloned hybridomas
were screened with the binding affinity of antibodies produced by the hybridomas against
CAPRIN-1 proteins as an index. One ug/ml solution of the CAPRIN-1 proteins prepared in
Example 3 described in WO2010/016526 was added to a 96-well plate at a concentration of
100 uL/well and left standing at 4°C for 18 hours. Each well was washed three times with
PBS-T. Then, a 0.5% BSA solution was added thereto at a concentration of 400 uL/well and
left standing at room temperature for 3 hours. The solution in each well was discarded, and
each well was washed three times with 400 uL of PBS-T. Then, the culture supernatant of
each hybridoma obtained above was added thereto at a concentration of 100 uL/well and left
standing at room temperature for 2 hours. Each well was washed three times with PBS-T.
Then, HRP-labeled anti-mouse IgG (H+L) antibodies (Invitrogen Corp.) diluted 5000-fold
with PBS were added thereto at a concentration of 100 ul/well and left standing at room
temperature for 1 hour. Each well was washed three times with PBS-T. Then, a TMB
substrate solution (Thermo Fisher Scientific Inc.) was added thereto at a concentration of 100
ul/well and left standing for 15 to 30 minutes to cause color reaction. After the color
development, the reaction was terminated by the addition of 1 N sulfuric acid at a
concentration of 100 ul/well. The absorbance was measured at 450 nm and 595 nm using an
absorption spectrometer. As a result, 112 hybridoma lines producing monoclonal antibodies
reactive with CAPPJN-l proteins were obtained.
[0122]
Next, these monoclonal antibodies were screened for antibodies reactive with the
surface of breast cancer cells expressing CAPRIN-1. Specifically, 106 cells of a human
breast cancer cell line MDA-MB-231V were centrifuged in a 1.5-mL microcentrifuge tube.

100 \iL of the culture supernatant of each hybridoma obtained above was added thereto and
left standing for 1 hour on ice. After washing with PBS, FITC-labeled goat anti-mouse IgG
antibodies (Invitrogen Corp.) diluted 500-fold with PBS containing 0.1% FBS were added
thereto and left standing for 1 hour on ice. After washing with PBS, the fluorescence
intensity was measured using FACS Calibur (Becton, Dickinson and Company). On the
other hand, the same operation as above was performed using the serum of each untreated 6-
week-old Balb/c mouse diluted 500-fold with a medium for hybridoma culture, instead of the
antibodies, to prepare a control. As a result, one monoclonal antibody (#1) having stronger
fluorescence intensity than that of the control, i.e., reactive with the surface of breast cancer
cells, was selected.
[0123]
Characterization of selected monoclonal antibody
The monoclonal antibodies obtained in Example 2 were analyzed according to a
method de; cribed in Example 5 of WO2010/016526 for their nucleotide sequences and amino
acid sequences encoded thereby. The resulting monoclonal antibody #1 is composed of a
heavy chaii L variable region of SEQ ID NO: 8 and a light chain variable region of SEQ ID NO:
12. The lesulting nucleotide sequence encoding the heavy chain variable region of the
monoclona antibody #1 is shown in SEQ ID NO: 13, and the amino acid sequence is shown in
SEQ ID N<): 8. The nucleotide sequence encoding the light chain variable region thereof is
shown in S iQ ID NO: 14, and the amino acid sequence is shown in SEQ ID NO: 12.
[0124]
Specifically, the monoclonal antibody #1 was confirmed to be composed of the heavy
chain varial »le region of SEQ ID NO: 8 and the light chain variable region of SEQ ID NO: 12,
wherein th< heavy chain variable region had CDR1, CDR2, and CDR3 consisting of amino
acid sequer ces of SEQ ID NOs: 5, 6, and 7, respectively, and the light chain variable region
had CDR1, CDR2, and CDR3 consisting of amino acid sequences of SEQ ID NOs: 9, 10, and
11, respectively.
[0125]

Preparation of human-mouse chimeric monoclonal antibody
Both ends of the gene amplification fragment comprising the nucleotide encoding the
heavy chain variable region of the mouse monoclonal antibody #1 obtained in Example 3,
which is represented by SEQ ID NO: 13, was treated with restriction enzymes, then purified,
and inserted according to a routine method into a pcDNA4/myc-His vector (Invitrogen Corp.)
already having gene inserts of a mouse antibody-derived leader sequence and a human IgGi H
chain constant region comprising SEQ ID NO: 37. Also, the gene amplification fragment
comprising the gene of the light chain variable region of the mouse monoclonal antibody #1
represented by SEQ ID NO: 14 was treated at both ends with restriction enzymes, then
purified, and inserted according to a routine method into a pcDNA3.1/myc-His (Invitrogen
Corp.) vector already having gene inserts of a mouse antibody-derived leader sequence and a
human IgGi L chain constant region comprising SEQ ID NO: 38.
[0126]
Next, the recombinant vector having the insert of the heavy chain variable region (SEQ
ID NO: 13) of the mouse monoclonal antibody #1 and the recombinant vector having the
insert of the light chain variable region (SEQ ID NO: 14) of the mouse monoclonal antibody
#1 were introduced into CHO-K1 cells (obtained from Riken Cell Bank). Specifically, 2 x
105 CHO-K1 cells were cultured in a Ham's F12 medium (Invitrogen Corp.) containing 1 mL
of 10% FBS per well of a 12-well culture plate, and washed with PBS(-). Then, a fresh
Ham's F12 medium containing 1 mL of 10% FBS per well was added thereto. 250 ng each
of the vectors lysed in 30 uL of OptiMEM (Invitrogen Corp.) was mixed with 30 uL of
Polyfect transfection reagent (Qiagen N.V.), and this mixture was added to each well. The
CHO-K1 cells cotransfected with the recombinant vectors were cultured in a Ham's F12
medium containing 10% FBS supplemented with 200 ug/mL Zeocin (Invitrogen Corp.) and
200 fj.g/mL Geneticin (Roche Diagnostics K.K.) and then inoculated to a 96-well plate at a
density of 0.5 cells/well to prepare a cell line stably producing a human-mouse chimeric
monoclonal antibody #1 (#1) having the variable regions of the mouse monoclonal antibody
#1.

[0127]
Each prepared cell line was cultured for 5 days in a 150-cm2 flask at a density of 5 x
105 cells/mL using 30 mL of a serum-free OptiCHO medium (Invitrogen Corp.) to obtain
culture supernatants containing human-mouse chimeric monoclonal antibody #1.
[0128]
Also, cell lines stably producing human-mouse chimeric comparative monoclonal
antibodies 1 to 11 were prepared in the same way as above using the following anti-CAPRIN-
1 mouse-derived monoclonal antibodies described in WO2010/016526 as comparative
antibodies: a comparative antibody 1 consisting of the heavy chain variable region of SEQ ID
NO: 15 and the light chain variable region of SEQ ID NO: 16; a comparative antibody 2
consisting of the heavy chain variable region of SEQ ID NO: 17 and the light chain variable
region of SEQ ID NO: 18; a comparative antibody 3 consisting of the heavy chain variable
region of SEQ ID NO: 19 and the light chain variable region of SEQ ID NO: 20; a
comparative antibody 4 consisting of the heavy chain variable region of SEQ ID NO: 21 and
the light chain variable region of SEQ ID NO: 22; a comparative antibody 5 consisting of the
heavy chain variable region of SEQ ID NO: 23 and the light chain variable region of SEQ ID
NO: 24; a comparative antibody 6 consisting of the heavy chain variable region of SEQ ID
NO: 25 and the light chain variable region of SEQ ID NO: 26; a comparative antibody 7
consisting of the heavy chain variable region of SEQ ID NO: 27 and the light chain variable
region of SEQ ID NO: 28; a comparative antibody 8 consisting of the heavy chain variable
region of SEQ ID NO: 29 and the light chain variable region of SEQ ID NO: 30; a
comparative antibody 9 consisting of the heavy chain variable region of SEQ ID NO: 31 and
the light chain variable region of SEQ ID NO: 32; a comparative antibody 10 consisting of the
heavy chain variable region of SEQ ID NO: 33 and the light chain variable region of SEQ ID
NO: 34; and a comparative antibody 11 consisting of the heavy chain variable region of SEQ
ID NO: 35 and the light chain variable region of SEQ ID NO: 36. Each prepared cell line
was cultured for 5 days in a 150-cm flask at a density of 5 x 10 cells/mL using 30 mL of a

serum-free OptiCHO medium (Invitrogen Corp.) to obtain culture supernatants containing any
of human-mouse chimeric comparative antibodies 1 to 11.
[0129]
Expression of CAPRIN-1 on surface of various cancer cells using anti-
CAPRIN-1 antibody #1
Next, the human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-
157, BT-20, MDA-MB-231V, and MRK-nu-1), the kidney cancer cell lines (Caki-1, Caki-2,
A498, and ACHN), the urinary bladder cancer cell line (T24), the ovary cancer cell line
(SKOV3), the lung cancer cell lines (QG56 and A549), the pancreatic cancer cell lines
(Capan-2 and MIAPaCa-2), the prostate cancer cell line (PC3), the uterine cervix cancer cell
line (SW756), the fibrosarcoma cell line (HT1080), the brain tumor cell lines (T98G, U87MG,
U251, SNB19, and U373), the gastric cancer cell lines (MNK28 and MNK45), the large bowel
cancer cell lines (HT29, Lovo, CaCo2, SW480, and HCT116), the leukemia cell line (AML5),
and the lymphoma cell line (Ramos) confirmed to have CAPRIN-1 gene expression were
examined for their expression of CAPRIN-1 proteins on the cell surface using the culture
supernatants containing #1 obtained in Example 4. 5 x 105 cells of each cell line were
centrifuged in each 1.5-mL microcentrifuge tube. Each culture supernatant (100 µL)
containing the antibody #1 was added to the tube and left standing for 1 hour on ice. After
washing with PBS, FITC-labeled goat anti-mouse IgG (H+L) antibodies (Jackson
ImmunoResearch Laboratories, Inc.) diluted with PBS containing 0.1% FBS were added
thereto and left standing at 4°C for 30 minutes. After washing with PBS, the fluorescence
intensity was measured using FACS Calibur (Becton, Dickinson and Company). The
negative control used was cells reacted only with secondary antibodies. As a result, the cells
supplemented with the antibody #1 had fluorescence intensity at least 35% stronger than that
of the negative control. This demonstrated that CAPRIN-1 proteins are expressed on the cell
membrane surface of the human cancer cell lines. The above rate of enhancement in
fluorescence intensity was indicated by the rate of increase in mean fluorescence intensity
(MFI) in each cell line and calculated according to the following expression:

Rate of increase in mean fluorescence intensity (Rate of enhancement in fluorescence
intensity) (%) = ((MFI of cells reacted with the anti-CAPRIN-1 antibodies) - (Control MFI)) /
(Control MFI) x 100.
[0130]

The anti-CAPRIN-1 human-mouse chimeric monoclonal antibody #1 obtained in
Example 4 was studied for its ability to damage CAPRIN-1-expressing cancer cells by ADCC
activity assay. The culture supernatant of the cells producing #1 was purified using Hitrap
Protein A Sepharose FF (GE Healthcare Bio-Sciences Ltd.). After replacement with PBS(-),
the solution was filtered through a 0.22-µm filter (Millipore Corp.). The resulting antibody
was used for activity assay. 106 cells each of the human breast cancer cell line MCF7, the
human large bowel cancer cell line HCT-116, the human pancreatic cancer cell line
MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell line
QG56 confirmed to have CAPRIN-1 expression were collected into a 50-mL centrifuge tube,
to which 100 µCi of chromium 51 was then added, followed by incubation at 37°C for 2 hours.
Then, the cells were washed three times with an RPMI1640 medium containing 10% FBS and
added at a density of 2 x 103 cells/well to each 96-well V-bottom plate to prepare target cells.
The purified antibody #1 and the human-mouse chimeric comparative antibodies 1 to 11
obtained in Example 4 were each added thereto at a concentration of 1 µg/well. A cell
population containing human NK cells separated using a routine method from human
peripheral blood lymphocytes was added to the plate at a density of 2 x 105 cells/well and
cultured at 37°C for 4 hours under conditions of 5% CO2. After the culture, the amount of
chromium 51 released from damaged tumor cells was measured in the culture supernatant to
calculate the cytotoxic activity of each anti-CAPRIN-1 antibody against the cancer cells. The
negative control used was cells supplemented with isotype control antibodies. The cell
population containing NK cells that was used in this evaluation was prepared as follows:
human peripheral blood mononuclear cells separated from human peripheral blood according
to a routine method using a specific gravity separation solution Histopaque for human

peripheral blood mononuclear cell separation (Sigma-Aldrich Corp.) were reacted with various
FITC-labeled antibodies (anti-human CD3 antibody, anti-human CD20 antibody, anti-human
CD 19 antibody, anti-human CDllc antibody, and anti-HLA-DR antibody (Becton, and
Dickinson and Company)), and a cell population unstained with the antibodies was separated
using a cell sorter (FACS Vantage SE (Becton, and Dickinson and Company)) or human NK
cell separation kit (Miltenyi Biotec K.K.). As a result of evaluating cytotoxic activity against
the cancer cells, the isotype control antibodies used and the comparative antibodies 1 to 11
used had cytotoxic activity less than 5% against each cell line. By contrast, the antibody #1
exhibited cytotoxic activity of 20%, 17%, 27%, and 10% against the human breast cancer cell
line MCF7, the human large bowel cancer cell line HCT-116, the human pancreatic cancer cell
line MIAPaCa-2, the human kidney cancer cell line Caki-2, and the human lung cancer cell
line QG56, respectively. Likewise, the isotype control antibodies used and the comparative
antibodies 1 to 11 used had cytotoxic activity less than 4% against all other cancer cells, breast
cancer cell lines ZR75-1, T47D, Hs578T, BT-20, SK-BR-3, MDA-MB-231V, and MRK-nu-1,
glioma cell lines T98G and U373, a lung cancer cell line A549, kidney cancer cell lines Caki-1
and ACHN, a uterine cervix cancer cell line SW756, a urinary bladder cancer cell line T24,
gastric cancer cell lines MKN28 and MKN45, a large bowel cancer cell line SW480, a
leukemia cell line AML5, and a lymphoma cell line Ramos. By contrast, the antibody #1
was confirmed to have 10% or higher cytotoxic activity against these cell lines. These results
showed that the obtained monoclonal antibody #1 against CAPRIN-1 damages CAPRIN-1 -
expressing cancer cells through its ADCC activity, and demonstrated that the antibody #1
exhibits stronger cytotoxic activity against human cancer cells than that of the comparative
antibodies 1 to 11.
[0131]
These results about cytotoxic activity were obtained by mixing the antibody against
CAPRIN-1 used in the present invention, lymphocyte cells (population containing NK cells),
and 2x10 cells of each cancer cell line with incorporated chromium 51, as described above,
followed by culturing the cells for 4 hours, after the culture, measuring the amount of

chromium 51 released into the medium, and calculating the cytotoxic activity against each
cancer cell line according to the following expression.
Expression: Cytotoxic activity (%) = Amount of chromium 51 released from the target
cells supplemented with the antibody against CAPRIN-1 and lymphocyte cells (population
containing NK cells) / Amount of chromium 51 released from target cells supplemented with 1
N hydrochloric acid x 100.
[0132]
Antitumor effect of anti-CAPRIN-1 monoclonal antibody on mouse in vivo
Next, the human-mouse chimeric monoclonal antibody #1 obtained in Example 4 was
evaluated for its antitumor effect on cancer-bearing mice in vivo. The antibody used was
column-purified from the culture supernatant of each cell line producing the antibody #1.
Similarly, the anti-CAPRIN-1 antibodies human-mouse chimeric comparative monoclonal
antibodies 1 to 11 prepared in Example 4 were also evaluated for their antitumor effects on
cancer-bearing mice in vivo.
[0133]
The antibody #1 was studied for its antitumor effect using cancer-bearing mice in
which a CAPRIN-1-expressing human-derived cancer cell line was transplanted. 2 x 106
human pancreatic cancer cell line Capan-2 cells (purchased from ATCC) per mouse were
subcutaneously transplanted into the backs of 65 Balb/c nude mice (Japan SLC, Inc.) and
grown until the size of tumor became approximately 5 mm in diameter. The antibody #1 and
the human-mouse chimeric comparative antibodies 1 to 11 were each intraperitoneally
administered at a dose of 200 µg (200 µl)/mouse to 5 (per antibody) of these cancer-bearing
mice. Then, each antibody was intraperitoneally administered to the cancer-bearing mice at
the same dose as above a total of three times for 2 days. The size of tumor was measured
every day, and the antitumor effect was observed. On the other hand, PBS(-) was
administered instead of the antibodies to the remaining 5 cancer-bearing mice, which were in
turn used as a control group. The size of tumor was calculated in terms of volume according
to the expression 0.5 x (Major axis x Minor axis x Minor axis).

[0134]
As a result of observing the antitumor effect, in the test group that received the
antibody #1 against CAPRIN-1, tumor proliferation was reduced to 70% at day 29 after the
antibody administration (with the tumor size in the control group at the same date defined as
100%). By contrast, in the mice that received the human-mouse chimeric comparative
antibodies 1 to 11, tumor proliferation was reduced to approximately 85%. These results
demonstrated that the obtained antibody #1 against CAPRIN-1 exerts an in vivo antitumor
effect on CAPRIN-1-expressing cancer cells. These results also demonstrated that the
antibody #1 exerts a stronger in vivo antitumor effect than that of the comparative antibodies 1
toll.
[0135]
The number of CAPRIN-1 molecules on surface of various cancer cells
recognized by anti-CAPRIN-1 antibody #1
Human breast cancer cell lines (ZR75-1, MCF7, T47D, SK-BR-3, MDA-MB-157, BT-
20, MDA-MB-231V, and MRK-nu-1), kidney cancer cell lines (Caki-1, Caki-2, A498, and
ACHN), a urinary bladder cancer cell line (T24), an ovary cancer cell line (SKOV3), lung
cancer cell lines (QG56 and A549), pancreatic cancer cell lines (MIAPaCa-2 and Capan-2), a
prostate cancer cell line (PC3), a uterine cervix cancer cell line (SW756), a fibrosarcoma cell
line (HT1080), brain tumor cell lines (T98G, U87MG, U251, SNB19, and U373), gastric
cancer cell lines (MNK28 and MNK45), large bowel cancer cell lines (HT29, Lovo, CaCo2,
SW480, and HCT116), a leukemia cell line (AML5), and a lymphoma cell line (Ramos) were
examined using an assay kit QIFIKIT for the number of molecules (Dako Japan Inc.) for the
number of CAPRIN-1 molecules on their cell surface recognized by the anti-CAPRIN-1
antibody #1. Similarly, the number of CAPRIN-1 molecules on the surface of these various
cancer cells was also examined using the comparative antibodies 1 to 11, which are anti-
CAPRIN-1 monoclonal antibodies prepared in Example 4.
[0136]

According to the protocol attached to the kit, the antibody #1 and comparative
antibodies 1 to 11 were diluted into 5 ug/mL (in terms of final concentration) with PBS, and
this dilution was added to each cell line and reacted for 30 minutes. After washing with PBS,
fluorescently labeled anti-mouse IgG antibodies attached to the kit were added as secondary
antibodies, together with calibration beads attached to the kit, to each cell line and left
standing for 45 minutes on ice. Each cell line and the calibration beads were washed with
PBS. Then, the fluorescence intensity was measured using FACS Calibur (Becton,
Dickinson and Company) to obtain a mean fluorescence intensity value (mean). Further,
comparative antibodies are measured similarly as above to obtain a mean. The negative
control used was cells reacted with isotype control antibodies, and a mean was also obtained.
Each mean fluorescence intensity value (mean) was used to calculate the number of molecules
according to the protocol attached to the kit. As a result, the number of CAPRIN-1
molecules on the surface of various cancer cells recognized by the antibody #1 was 105 or
more per cell for all the examined human cancer cell lines. On the other hand, the number of
molecules recognized by the comparative monoclonal antibodies 1 to 11 was less than 105 per
cell.
Industrial Applicability
[0137]
The antibody of the present invention is useful in the treatment and/or prevention of
cancer.
All publications, patents, and patent applications cited herein are incorporated herein by
reference in their entirety.

We. Claims
[Claim 1]
An antibody or a fragment thereof which has immunological reactivity with a
CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable
region comprising complementarity determining regions of SEQ ID NOs: 5, 6, and 7 and a
light chain variable region comprising complementarity determining regions of SEQ ID NOs:
9, 10, and 11.
[Claim 2]
The antibody or the fragment thereof according to claim 1, wherein the antibody is a
human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, or a
multispecific antibody.
[Claim 3]
The antibody or the fragment thereof according to claim 1 or 2, wherein the antibody or
the fragment thereof is conjugated with an antitumor agent.
[Claim 4]
A pharmaceutical composition for treatment and/or prevention of cancer, comprising an
antibody or a fragment thereof according to any one of claims 1 to 3 as an active ingredient.
[Claim 5]
The pharmaceutical composition according to claim 4, wherein the cancer is breast
cancer, kidney cancer, pancreatic cancer, large bowel cancer, lung cancer, brain tumor, gastric
cancer, uterine cervix cancer, ovary cancer, prostate cancer, urinary bladder cancer,
esophageal cancer, leukemia, lymphoma, fibrosarcoma, mastocytoma, or melanoma.
[Claim 6]
A pharmaceutical combination for treatment and/or prevention of cancer, comprising a
pharmaceutical composition according to claim 4 or 5 and a pharmaceutical composition
comprising an antitumor agent.
[Claim 7]

A DNA encoding an antibody or a fragment thereof according to claim 1 or 2.
[Claim 8]
A method for treating and/or preventing cancer, comprising administering an antibody
or a fragment thereof according to any one of claims 1 to 3, a pharmaceutical composition
according to claim 4 or 5, or a pharmaceutical combination according to claim 6 to a test
subject.